Primary data collection for the Phase 3 trial (NCT06421870) investigating the renoprotective effects of dapagliflozin in patients with chronic kidney disease was completed on May 31, 2025. This study enrolled 210 participants to compare dapagliflozin against pentoxifylline.
Background
The kidneys play a crucial role in glucose homeostasis, partly through SGLT2. SGLT2 inhibitors, such as dapagliflozin, have demonstrated beneficial effects in reducing the onset and progression of renal complications in individuals with and without diabetes. These effects include slowing the decline in glomerular filtration rate (GFR), delaying the onset of microalbuminuria, and slowing or reversing the progression of proteinuria.
Trial design
The study, titled "Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients" (NCT06421870), is a Phase 3 trial. It enrolled 210 participants diagnosed with Chronic Kidney Diseases. The interventions being compared are dapagliflozin 10mg tab and pentoxifylline 400 mg.
What this means
The completion of primary data collection for this Phase 3 trial signifies that all necessary patient data has been gathered for analysis. This study directly compares the renoprotective effects of dapagliflozin with pentoxifylline, which is important for clinicians evaluating treatment options for patients with chronic kidney disease. The forthcoming results will be crucial in further defining the role of dapagliflozin in managing renal complications and could influence future clinical guidelines and patient care strategies.
Source
Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06421870, titled "Renoprotective Effects of Dapagliflozin Versus Pentoxiphylline in Chronic Kidney Disease Patients," was noted on May 31, 2025, on clinicaltrials.gov.